Entry into a Material Definitive Agreement Asset Purchase Agreement and Pre-Funded Warrant On August 17, 2026 (the “Closing Date”), Cypherpunk Technologies Inc., a Delaware corporation (the “Company”) entered into an Asset Purchase Agreement (the “APA”) with Moria Mining, LLC, a Delaware limited liability company (the “Seller”), Winklevoss Treasury Investments, LLC, a Delaware limited liability company and an affiliate of Seller (“WTI” and together with Seller, the “Seller Parties”), and Cyph…

The Pre-Funded Warrant was, or will be, as the case may be, offered and sold pursuant to an exemption from the registration requirements of were, or will be, as the case may be, of the Securities Act of 1933, as amended (the “Securities Act”), under Section 4(a)(2) and Rule 506(b) of Regulation D of the Securities Act. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of…

Results of Operations and Financial Condition On August 12, 2026, Cypherpunk Technologies Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 20, 2026, Cypherpunk Technologies Inc. (the “Company”) received a notification letter (the “Closing Bid Price Deficiency Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required fo…

Results of Operations and Financial Condition On May 14, 2026, Cypherpunk Technologies Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or af…

Director — Dr. Christopher Mirabelli, Dr. Joseph Loscalzo, Dr. Richard Schilsky, Dr. James Cavanaugh: Multiple directors are retiring from the Board of Directors.

Results of Operations and Financial Condition On March 16, 2026, Cypherpunk Technologies Inc. (the “Company”) announced its financial results for the year ended December 31, 2025. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 4, 2026, Cypherpunk Technologies Inc. (the “Company”) received a notification letter (the “Closing Bid Price Deficiency Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required fo…

Termination of a Material Definitive Agreement. The information set forth under

Entry into a Material Definitive Agreement. RSU Grant to Consultant As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 12, 2025 (the “November 12, 2025 Form 8-K”), Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.), a Delaware company (the “Company”), entered into a Consulting Agreement with CoinXit Ltd. (“CoinXit”), dated November 11, 2025 (the “Consulting Agreement”), pursuant to which the Company previously a…

Annual board election with no significant changes in senior management.

Entry into a Material Definitive Agreement. On November 19, 2025, Cypherpunk Technologies Inc. (f./k/a Leap Therapeutics, Inc.), a Delaware corporation (the “Company”), entered into a Waiver and Modification Agreement (the “Agreement”) with Winklevoss Treasury Investments, LLC (“Winklevoss Capital”), which modifies and waives certain provisions of the Common Warrant, dated October 8, 2025, issued by the Company in favor of Winklevoss Capital (the “WTI Common Warrant”) in connection with the p…

Results of Operations and Financial Condition. On November 12, 2025, the Company issued a press release announcing its financial results for the third quarter ended September 30, 2025. The text of the press release is included as Exhibit 99.2 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.2 hereto, is being “furnished” and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…

Other Events. ZEC Purchases As discussed under Item 7.01, on November 12, 2025, the Company issued a press release announcing the Name Change and unveiled a digital asset treasury strategy to accumulate Zcash’s native coin, ZEC. The Company has to date used $50 million of proceeds from the previously announced Private Placement to purchase 203,775 ZEC at a weighted average cost of $245.37 per token, for an aggregate purchase price of $50 million. Ticker Symbol Change In connection with the Na…

Entry into a Material Definitive Agreement. On November 12, 2025, Cypherpunk Technologies Inc. (f./k/a Leap Therapeutics, Inc.), a Delaware corporation (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which the Company may offer and sell shares of its common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $200,000,000 from time to time to or t…

The excerpt does not provide specific details about any particular movement or change.

Regulation FD Disclosure On November 12, 2025, the Company issued a press release announcing the Name Change and unveiled a digital asset treasury strategy to accumulate Zcash’s native coin, ZEC. The Company has to date used $50 million of proceeds from the previously announced Private Placement to purchase 203,775 ZEC at a weighted average cost of $245.37 per token, for an aggregate purchase price of $50 million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report…

Entry into a Material Definitive Agreement. Consulting Agreement On November 11, 2025, Cypherpunk Technologies Inc. (f./k/a Leap Therapeutics, Inc.), a Delaware corporation (the “Company”), entered into a Consulting Agreement (the “Consulting Agreement”) with CoinXit Ltd. (“CoinXit”), effective as of November 11, 2025. Under the Consulting Agreement, CoinXit will provide consulting services to the Company as set forth in project assignments to be mutually agreed from time to time. Mr. Khing O…

Regulation FD Disclosure. On October 9, 2025, the Company issued a press release announcing the Closing of the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is deemed to have been furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liab…

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

Entry Into a Material Definitive Agreement. Securities Purchase Agreement On October 6, 2025, Leap Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with the investors named therein (the “ Purchasers ”), for the private placement (the “ Private Placement ”) of (i) an aggregate of 15,212,311 shares (the “ Shares ”) of common stock of the Company, par value $0.001 per share (the “ Common Stock ”), a…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on March 12, 2025, Leap Therapeutics, Inc. (the “Company”) received a notification letter (the “Closing Bid Price Deficiency Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the previous 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimu…

Results of Operations and Financial Condition On August 14, 2025, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after…

Costs Associated with Exit or Disposal Activities Due to current market conditions and the financial position of Leap Therapeutics, Inc. (the “Company”), the Company’s Board of Directors has approved a series of measures to conserve cash and reduce operating costs, including (i) the completion of the DeFianCe clinical trial and the wind-down of the Company’s research and development activities, including the Company’s sirexatamab and FL-501 development programs, and (ii) a reduction in force…

Chief Operating Officer, Chief Medical Officer — Augustine Lawlor, Cyndi Sirard, MD: Terminated without cause as part of a reduction in force.